ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Proesmans, M.
Right arrow Articles by de Boeck, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Proesmans, M.
Right arrow Articles by de Boeck, K.
Eur Respir J 2006; 27:937-943
Copyright ©ERS Journals Ltd 2006

Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre

M. Proesmans1, W. Balinska-Miskiewicz2, L. Dupont3, X. Bossuyt4, J. Verhaegen5, N. Høiby6 and K. de Boeck1

Depts of 1 Paediatric Pulmonology, 3 Adult Pulmonology, 4 Laboratory Medicine, Immunology, and 5 Microbiology, University Hospital Gasthuisberg, Leuven, Belgium, 2 Dept of Paediatrics, Allergology and Cardiology, Wroclaw Medical University, Wroclaw, Poland, 6 Dept of Microbiology, Rigshospitalet, University of Copenhagen, Denmark.

CORRESPONDENCE: K. de Boeck, University Hospital Gasthuisberg Leuven, Paediatric Pulmonology, Herestraat 49, 3000 Leuven, Belgium. Fax: 32 16343842. E-mail: christiane.deboeck{at}uz.kuleuven.ac.be

Keywords: Anti-pseudomonal antibodies, chronic lung infection, cystic fibrosis, Pseudomonas aeruginosa

Received: August 26, 2005
Accepted December 10, 2005

Four separate categories of chronic Pseudomonas aeruginosa (Pa) infection in children with cystic fibrosis (CF) have been previously defined, based on airway cultures taken over the previous year.

The aim of the present study was to evaluate this definition in the current authors' paediatric and adult CF clinic using clinical, immunological and lung function parameters.

During follow-up, out of 193 patients, 55 (34%) CF patients had never been infected with Pa, 27 (17%) were free of Pa, 29 (18%) were intermittently infected and 51 (31%) were chronically infected. Disease severity markers, such as lung function, were significantly worse in the chronic group, especially in the paediatric population. Differences in adult patients were smaller and no longer significant. Pa antibodies differed strongly between the groups, and were very high (mean±SD 55.4±5.5) and highly statistically significant from all other groups in the chronic group. They were low and different from all other groups in the never group (1.8±0.6). Pa antibodies did not differ between the free of Pa and the intermittent group.

In conclusion, the current authors confirmed an agreement between Pseudomonas aeruginosa status according to the new definition and clinical status, as well as with the level of Pseudomonas aeruginosa antibodies.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
R. Vos, B. M. Vanaudenaerde, N. Geudens, L. J. Dupont, D. E. Van Raemdonck, and G. M. Verleden
Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation?
Eur. Respir. J., May 1, 2008; 31(5): 1037 - 1045.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.